Category: Pα+ - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Post published:July 14, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Funding Update: Q2 2025

Psychedelic Funding Update: Q2 2025

Post published:July 9, 2025
Post category:Analysis Pα+

Read more about the article From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Post published:July 7, 2025
Post category:Interviews Pα+

Read more about the article Oregon Psilocybin Services Tracker: Q1 2025

Oregon Psilocybin Services Tracker: Q1 2025

Post published:July 4, 2025
Post category:Analysis Pα+

Read more about the article Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Beckley and atai Leadership Unpack Phase 2b Data, Take Aim at GH’s Dosing Model

Post published:July 1, 2025
Post category:Analysis News Pα+

Read more about the article Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

Post published:July 1, 2025
Post category:Interviews Pα+

Read more about the article Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

Post published:June 28, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber; Judge Recommends Schedule I Placement for DOI and DOC

Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber; Judge Recommends Schedule I Placement for DOI and DOC

Post published:June 27, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

Post published:June 25, 2025
Post category:Analysis News Pα+

Read more about the article Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program

Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program

Post published:June 18, 2025
Post category:Analysis News Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.